Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 21 clinical trials
Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy

immunotherapies targeted therapies (BRAF or MEK inhibitors), can induce faster and higher response rates, but often of shorter duration, even when combined. Initial attempts of combining vemurafenib or

  • 6 views
  • 24 Jan, 2021
  • 13 locations
Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis

Prospective, interventional, open, randomized, single-center, non-commercial clinical trial to optimize treatment and dosage of vemurafenib in juvenile patients with histiocytosis resistant to

  • 0 views
  • 08 Jul, 2021
  • 1 location
  • 0 views
  • 05 Jul, 2021
  • 1 location
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

cancer cells. Vemurafenib has been tested to treat these people. However, researchers think a combination of drugs might work better. Objective To test if treatment

  • 0 views
  • 12 Sep, 2021
  • 1 location
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphomas or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

antineoplastic
blood transfusion
palbociclib
graft-versus-host disease
tumor markers
  • 997 views
  • 12 Sep, 2021
  • 114 locations
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

also being done to find out the highest doses of copanlisib and vemurafenib that, when given in combination, do not cause serious side effects, and whether the study treatment will make radioiodine

external beam radiation therapy
gilbert's syndrome
BRAF
platelet count
measurable disease
  • 0 views
  • 25 Mar, 2021
  • 7 locations
Combination or Sequence of Vemurafenib Cobimetinib and Atezolizumab in High-risk Resectable Melanoma

Neoadjuvant plus adjuvant treatment with target therapy and immunotherapy given in combination or sequence may have an anti-tumour activity and may reduce the risk of relapse in patients with high-risk resectable melanoma (stage III B / C / D and oligometastatic stage IV).

  • 0 views
  • 01 Feb, 2021
  • 6 locations
A Combination of Vemurafenib Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation

disease reactivation. Considering this a trial that combines targeted therapy (vemurafenib) and low-dose chemotherapy (cytarabine and 2-chlorodeoxyadenosine) in order to achieve complete response

  • 0 views
  • 24 Jan, 2021
  • 1 location
Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)

This clinical trial aims to evaluate the efficacy, safety of FOLFIRI with vemurafenib and cetuximab in Advanced Colorectal Cancer Patients with BRAF V600E mutation.

adenocarcinoma
folfiri regimen
BRAF
colorectal adenocarcinoma
cetuximab
  • 7 views
  • 28 Aug, 2021
  • 1 location
Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

This phase II trial studies how well vemurafenib and cobimetinib work in treating patients with BRAF V600E mutation positive craniopharyngioma. Vemurafenib and cobimetinib may stop the growth of

  • 76 views
  • 19 Jun, 2021
  • 108 locations